Global Polymerase Chain Reaction (PCR) Market Analysis Report 2022: An $18.44 Billion Market by 2030 - Rising Forensic and Research Applications - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Polymerase Chain Reaction Market Size, Share & Trends Analysis Report by Type (Conventional PCR), by Product (Instruments, Consumables & Reagents, Software & Services), by Application, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

The global polymerase chain reaction market size is expected to reach USD 18.44 billion by 2030. It is expected to expand at a CAGR of 7.5% from 2022 to 2030.

The demand for polymerase chain reaction (PCR) testing is expected to be driven by the increasing demand for advanced diagnostic techniques; rising forensic and research applications; and the growing prevalence of diseases such as chronic diseases, infectious diseases, and genetic disorders.

Moreover, increasing demand for genetic testing procedures and the introduction of novel technologies are other key factors likely to increase the demand for PCR testing.

The market is expected to witness growth opportunities owing to factors such as the increasing adoption of advanced diagnostic tests and the growing adoption of PCR technologies in medical and non-medical applications.

Moreover, the launch of novel technologies, an increasing number of CROs, and research and forensic laboratories are expected to propel the demand forward during the forecast period. Several research institutes and CROs are involved in genomics-based research to develop innovative strategies for disease management.

The introduction of novel and technologically advanced tests is opening new growth opportunities. For instance, in January 2021, GeneIQ announced the launch of its 4-in-1 PCR test for the detection of influenza B (Flu B), influenza A (Flu A), respiratory syncytial virus (RSV), and SARS-CoV-2. Similarly, in December 2020, Menarini Diagnostics launched a molecular test that is used to distinguish between Flu and SARS-CoV-2. Such initiatives will increase the demand for novel PCR tests.

Favorable initiatives undertaken by government bodies are encouraging the players to develop novel molecular tests for different applications. For instance, in January 2020, the University of Helsinki in collaboration with the European Union under the EU/EFPIA Innovative Medicines Initiative Joint Undertaking, funded research for the assessment of qPCR for microbiota profiling.

In the study, the iCycler iQ thermal cycler system was used with HOT FIREPol EvaGreen qPCR Mix Plus for studying Clostridium cluster XIVa. Moreover, in March 2020, International Atomic Energy Agency (IAEA) announced a partnership with the Food and Agriculture Organization of the United Nations (FAO) for supporting the use of reverse transcription-PCR.

Several companies are adopting strategies such as acquisitions for strengthening their positions. Acquisition assists companies to enhance their offerings, capabilities, and competencies.

For instance, in January 2021, Thermo Fisher Scientific, Inc. announced that it has acquired Mesa Biotech, Inc. - a molecular diagnostic company for USD 450 million to strengthen its product portfolio. Thus, various strategies adopted by companies are anticipated to propel the demand forward over the forecast period.

Polymerase Chain Reaction Market Report Highlights

• In 2021, the medical application segment dominated the market owing to the rising application of PCR in clinical diagnostics and drug development and research
• The consumables and reagents product segment held the largest revenue share in 2021 and is expected to retain its dominance over the forecast period
• North America dominated the market in 2021 due to the presence of favorable regulations and various initiatives about the advancements in healthcare infrastructure undertaken by the government and the high prevalence of diseases in the region

Company Profiles

• Abbott
• Qiagen
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Thermo Fisher Scientific, Inc.
• Cytiva (GE Healthcare)
• bioMerieux SA
• F. Hoffmann-La Roche Ltd.
• Fluidigm Corporation
• STILLA
• Microsynth AG
• JN Medsys
• Danaher Corporation

Market Dynamics

Market Drivers

• Rising incidence of chronic diseases, infectious diseases, and genetic disorders
• Technological advancements in PCR
• Implementation of MIQE guidelines
• Increasing demand for rapid diagnostic tests and growing adoption of PCR technologies
• Increasing number of CROs and forensic & research laboratories
• Increasing demand for prenatal genetic testing procedures
• Outbreak of COVID-19

Market Restraint Analysis

• High qPCR device costs
• Stringent regulatory policies

Reimbursement & Regulatory Scenario

Major Deals & Strategic Alliances

• New Product Launch
• Acquisition
• Expansion
• Partnerships
• Marketing & Promotions
• Market entry strategies
• Unmet Need Analysis
• Need for rapid diagnosis
• Affordability
• Limited scope of pathogen detection
• Change In Market Dynamics After The Launch Of Novel PCR Devices
• Medical
• Non-Medical
• Comparison Of Existing PCR With Plasmonic PCR
• Potential for COVID-19
• Consumer Behavior Analysis

For more information about this report visit https://www.researchandmarkets.com/r/et61x6